An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging

被引:15
|
作者
Wanet, Marie [1 ]
Delor, Antoine [2 ]
Hanin, Francois-Xavier [3 ]
Ghaye, Benoit [4 ]
Van Maanen, Aline [5 ]
Remouchamps, Vincent [6 ]
Clermont, Christian [6 ]
Goossens, Samuel [1 ]
Lee, John Aldo [1 ]
Janssens, Guillaume [1 ]
Bol, Anne [1 ]
Geets, Xavier [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Mol Imaging Radiotherapy & Oncol MIRO, Ave Hippocrate,54 Bte B1-54-07, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Radiat Oncol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Dept Nucl Med, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium
[5] Clin Univ St Luc, Stat Support Unit, Canc Ctr, B-1200 Brussels, Belgium
[6] CHU UCL Namur, Dept Radiat Oncol, Clin & Maternite St Elisabeth Namur, B-5000 Namur, Belgium
关键词
Non-small cell lung cancer; Dose escalation; FDG-PET imaging; Intensity modulated radiotherapy; Toxicity; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; NORMAL TISSUE CONSTRAINTS; THERAPY ONCOLOGY GROUP; PHASE-II; CONCURRENT CHEMORADIATION; THORACIC RADIOTHERAPY; RESPONSE EVALUATION; NSCLC PATIENTS; SOLID TUMORS;
D O I
10.1007/s00066-017-1168-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. Patients and methods total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes). The fraction dose was increased within the individual PET-based PTV (PTVPET) using intensity modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) until the predefined organ-at-risk (OAR) threshold was reached. Tumor response was assessed during follow-up by means of repeat FDG-PET/computed tomography. Acute and late toxicity were recorded and classified according to the CTCAE criteria (Version 4.0). Local progression-free survival was determined using the Kaplan-Meier method. Results The average dose to PTVPET reached 89.17 Gy for peripheral and 75 Gy for central tumors. After a median follow-up period of 29 months, seven patients were still alive, while six had died (four due to distant progression, two due to grade 5 toxicity). Local progression was seen in two patients in association with further recurrences. One and 2-year local progression free survival rates were 76.9% and 52.8%, respectively. Three cases of acute grade 3 esophagitis were seen. Two patients with central tumors developed late toxicity and died due to severe hemoptysis. Conclusion hese results suggest that a non-uniform and individualized dose escalation based on FDG-PET in IMRT delivery is feasible. The doses reached were higher in patients with peripheral compared to central tumors. This strategy enables good local control to be achieved at acceptable toxicity rates. However, dose escalation in centrally located tumors with direct invasion of mediastinal organs must be performed with great caution in order to avoid severe late toxicity.
引用
收藏
页码:812 / 822
页数:11
相关论文
共 50 条
  • [41] Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
    Kepka, Lucyna
    Tyc-Szczepaniak, Dobromira
    Bujko, Krzysztof
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (07) : 853 - 861
  • [42] Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer
    Watanabe, H
    Yamamoto, N
    Tamura, T
    Shimoyama, T
    Hotta, K
    Inoue, A
    Sawada, M
    Akiyama, Y
    Kusaba, H
    Nokihara, H
    Sekine, I
    Kunitoh, H
    Ohe, Y
    Kodama, T
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (12) : 626 - 630
  • [43] Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?
    Hong, Julian C.
    Salama, Joseph K.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 126 - 133
  • [44] PROGNOSTIC VALUE OF FDG-PET/CT VOLUMETRIC PROGNOSTIC STAGING SYSTEM IN NON-SMALL CELL LUNG CANER
    Pu, Yonglin
    Zhang, Hao
    Penney, Bill
    Shih, Ming Chi
    Jiang, Yulei
    Chen, Chin-Tu
    Daniel, Appelbaum
    Kao, Chien-Min
    Carey, George
    Salgia, Ravi
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S252 - S253
  • [45] The role of radiation therapy in non-small cell lung cancer
    Mohiuddin, MM
    Choi, NC
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) : 278 - 288
  • [46] Staging of non-small-cell lung cancer and application of FDG-PET - A cost modeling approach
    Verboom, P
    Herder, GJM
    Hoekstra, OS
    Smit, EF
    van den Bergh, JHAM
    van Velthoven, PCM
    Grijseels, EWM
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (03) : 576 - 585
  • [47] Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma
    Duan, X. -Y.
    Wang, W.
    Li, M.
    Li, Y.
    Guo, Y. -M.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2015, 48 (03) : 267 - 272
  • [48] Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose Limiting normal tissues and radiation dose-escalation:: A planning study
    De Ruysscher, D
    Wanders, S
    Minken, A
    Lumens, A
    Schiffelers, J
    Stultiens, C
    Halders, S
    Boersma, L
    van Baardwijk, A
    Verschueren, T
    Hochstenbag, M
    Snoep, G
    Wouters, B
    Nijsten, S
    Bentzen, SM
    van Kroonenburgh, M
    Öllers, M
    Lambin, P
    RADIOTHERAPY AND ONCOLOGY, 2005, 77 (01) : 5 - 10
  • [49] Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapy
    Panettieri, Vanessa
    Malik, Zafar I.
    Eswar, Chinnamani V.
    Landau, David B.
    Thornton, John M. C.
    Nahum, Alan E.
    Mayles, W. Philip M.
    Fenwick, John D.
    RADIOTHERAPY AND ONCOLOGY, 2010, 97 (03) : 418 - 424
  • [50] Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial
    Rimner, Andreas
    Gelblum, Daphna Y.
    Wu, Abraham J.
    Shepherd, Annemarie F.
    Mueller, Boris
    Zhang, Siyuan
    Cuaron, John
    Shaverdian, Narek
    Flynn, Jessica
    Fiasconaro, Megan
    Zhang, Zhigang
    von Reibnitz, Donata
    Li, Henry
    McKnight, Dominique
    McCune, Megan
    Gelb, Emily
    Gomez, Daniel R.
    Simone, Charles B.
    Deasy, Joseph O.
    Yorke, Ellen D.
    Ng, Kenneth K.
    Chaft, Jamie E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (03): : 869 - 877